Literature DB >> 659591

3,3'-Diiodothyronine production, a major pathway of peripheral iodothyronine metabolism in man.

L A Gavin, M E Hammond, J N Castle, R R Cavalieri.   

Abstract

3,3'-Diiodothyronine (3,3'-T(2)) has been detected in human serum and in thyroglobulin. However, no quantitative assessment of its clearance rate (CR), production rate (PR), or of the importance of extrathyroidal sources of 3,3'-T(2) relative to direct thyroidal secretion is yet available. This study examines these parameters in seven euthyroid subjects, and in eight athyreotic subjects (H) eumetabolic due to thyroxine therapy (HT(4)) (n = 5) or triiodothyronine replacement (HT(3)) (n = 3). A highly specific radioimmunoassay for the measurement of 3,3'-T(2) in whole serum was developed. Serum 3,3'-T(2) concentrations were (mean +/- SD) 6.0+/-1.0 ng/100 ml in 13 normal subjects, 9.0+/-4.6 ng/100 ml in 25 hyperthyroid patients, and 2.7+/-1.1 ng/100 ml in 17 hypothyroid patients. The values in each of the latter two groups were significantly different from normal. 3,3'-T(2) was detected regularly in normal concentrations in 11 hypothyroid patients eumetabolic by treatment with synthetic T(4), in 10 eumetabolic patients suffering from nonthyroidal systemic illness, and in 2 subjects with elevated serum T(4)-binding globulin. The 3,3'-T(2) CR was assessed from data acquired from the (125)I-3,3'-T(2) constant infusion technique. The 3,3'-T(2) PR was calculated from CR and serum concentration of 3,3'-T(2) determined by radio-immunoassay. In the HT(4) subjects the 3,3'-T(2) CR averaged 840+/-377 liters/day and 3,3'-T(2) PR 33.9+/-12.5 mug/day. These results were not significantly different from those in the control group: 3,3'-T(2) CR 628+/-218 liters/day and 3,3'-T(2) PR 39.8+/-19.8 mug/day (all corrected to 70 kg body wt). In addition to 3,3'-T(2) PR, T(3), and reverse triiodothyronine (rT(3)) PR were determined in three of the HT(4) subjects. In each case studied, the 3,3'-T(2) PR was close to the combined triiodothyronine (T(3) + rT(3)) PR. The mean molar ratio of T(2) PR/(T(3) + rT(3)) PR was 1.08+/-0.10. The results obtained in the HT(4) subjects indicate that the production of 3,3'-T(2) is a major route of T(4) metabolism. The combined studies of 3,3'-T(2), T(3) and rT(3) PR in the HT(4) subjects indicate that both T(3) and rT(3) are major precursors of 3,3'-T(2). In the HT(3) subjects, the conversion of T(3) to 3,3'-T(2), determined as the molar ratio of 3,3'-T(2) PR to T(3) PR, ranged from 0.36 to 0.92, providing further evidence that T(3) is a precursor of 3,3'-T(2). From the close agreement between the mean values for 3,3'-T(2) PR in the euthyroid and HT(4) group it is concluded that most, if not all of the 3,3'-T(2) produced in normal humans is derived by extrathyroidal conversion from T(3) and rT(3).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659591      PMCID: PMC372649          DOI: 10.1172/JCI109044

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Activities of thyroid hormones and related compounds in an in vitro thymocyte assay.

Authors:  I D Goldfine; G J Smith; C G Simons; S H Ingbar; E C Jorgensen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

2.  Serum 3,3'-L-diiodothyronine, a direct radioimmunoassay in human serum: method and clinical results.

Authors:  A Burger; C Sakoloff
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

3.  An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man.

Authors:  I J Chopra
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

4.  Separation of iodo compounds in serum by chromatography on Sephadex columns.

Authors:  W L Green
Journal:  J Chromatogr       Date:  1972-10-05

5.  A radioimmunoassay for 3,3'-L-diiodothyronine (3,3'T2).

Authors:  K D Burman; D Strum; R C Dimond; Y Y Djuh; F D Wright; J M Earll; L Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

6.  A single method for measuring total thyroxine and free thyroxine index in serum.

Authors:  C Abreau; A Vagenakis; F Azizi; G Portnay; L Braverman
Journal:  J Nucl Med       Date:  1973-10       Impact factor: 10.057

7.  Radioimmunoassay for triiodothyronine (T 3 ): I. Affinity and specificity of the antibody for T 3 .

Authors:  H Gharib; R J Ryan; W E Mayberry; T Hockert
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

8.  A radioimmunoassay for measurement of 3,3'-L-diiodothyronine (T2).

Authors:  S Y Wu; I J Chopra; Y Nakamura; D H Solomon; L R Bennett
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

9.  Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man.

Authors:  J T Nicoloff; J C Low; J H Dussault; D A Fisher
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

10.  Direct immunoassay of triiodothyronine in human serum.

Authors:  P R Larsen
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

View more
  4 in total

1.  The effect of iodothyronines on the conversion of thyroxine into 3,3'-5-tri-iodothyronine in isolated rat renal tubules.

Authors:  P Heyma; R G Larkins; D G Campbell
Journal:  Biochem J       Date:  1980-08-15       Impact factor: 3.857

2.  3,3'-Diiodothyronine concentrations in hospitalized or thyroidectomized patients: results from a pilot study.

Authors:  Jacqueline Jonklaas; Anpalakan Sathasivam; Hong Wang; David Finigan; Offie P Soldin; Kenneth D Burman; Steven J Soldin
Journal:  Endocr Pract       Date:  2014-08       Impact factor: 3.443

Review 3.  Physiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

4.  Factors altering thyroid hormone metabolism.

Authors:  J Robbins
Journal:  Environ Health Perspect       Date:  1981-04       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.